Contergan Victim Wins Against Former Board Member of the Contergan Foundation

Food and Healthcare Press Releases Thursday June 8, 2017 09:32
COLOGNE, Germany--8 Jun--PRNewswire/InfoQuest

In the lawsuit between the plaintiff, Contergan (thalidomide) victim Andreas Meyer, and the defendant and former Board member of the Contergan Foundation, Attorney Karl Schucht, the Bonn Regional Court came to a judgement on 10.5.2017. The judgement is not yet final. The case concerns the question of possible collaboration between Gruenenthal and the Federal German Contergan Foundation.

Meyer was and will be represented by Prof. Dr. Jan Hegemann from the law firm Raue Rechtsanwalte LLP in Berlin.
Please refer the full press release dated 08.06.2017 at: http://www.gruenenthal-opfer.de/press_ContVict_wins_agains_memb_ContFound_8_6_2017
You can read the judgement and further information at the following link:
http://www.gruenenthal-opfer.de/Materials_Judgement_Meyer_vs_Schucht_10_05_2017
Contact:
Federation of Thalidomide Sufferers and Gruenenthal Victims
c/o Mr Andreas Meyer (Chairman)
Dohmengasse 7
50829 Koln
Email: bcg-brd-dachverband@gmx.de
Website: www.gruenenthal-opfer.de
Mobile: +49 (0)172 / 2905974
Source: Federation of Thalidomide Sufferers and Gruenenthal Victims

Latest Press Release

ESMO Publishes New Position Paper on Supportive and Palliative Care

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757 ], calling attention to the evolving and growing gap between the needs of cancer...

Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

The medical device company is transforming neurological treatments through its non-invasive focused ultrasound applications Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies,...

MediaTek Sensio: New Biosensor Solution Brings Health Monitoring to Smartphones

MediaTek Inc. today unveiled MediaTek Sensio(TM), the first 6-in-1 smartphone biosensor module. MediaTek Sensio is a powerful advanced health monitoring solution which makes it easy to track heart rate information, blood pressure trends, peripheral...

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Related Topics